Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We are pleased to announce that Prof Joel Tarning has been awarded the biennial Grahame-Smith Prize by the British Pharmacological Society for outstanding contributions to clinical pharmacology. Joel has headed MORU's Clinical Pharmacology Department since 2012. Since then, the Department has grown into large, productive group that conducts laboratory- and computer-based pharmacology research.

Profesor Joel Tarning in a laboratory. © 2020 MORU. Photographer: Gerhard Jørén

Prof David Grahame-Smith, after whom the award Joel was honoured with is named, was Professor of Pharmacology at Oxford for several decades,” said Prof Nick Day, MORU Director. “He taught me as a medical student, and both Nick White and I both worked for him as junior doctors. He was a wonderful man, very funny and deeply humane in his clinical practice. It is very fitting that Joel has won an award associated with such a giant in the field.”

Joel's research interests include infectious disease pharmacology and the use of novel pharmacometric methodologies to identify and optimise the dose in particularly vulnerable populations, such as children and pregnant women. His work on the pharmacokinetic and pharmacodynamic properties of antimalarial drugs in young children with uncomplicated and severe malaria has already had a global impact, resulting in revised WHO Guidelines for the treatment of malaria. 

"David Grahame-Smith was a wonderful man," said Prof Sir Nick White. "Nick Day and I both worked for him. He was cheerful, positive, amusing and down to earth as well as being a world leading clinical pharmacologist and a very good physician. He was also an excellent jazz pianist. It is really nice for Joel to have deservedly won this award and, in doing so, to revive his memory."

As part of his award, Joel has been invited to give a prize lecture at a future, physical meeting of the Society. Please join us in extending your congratulations to Joel.

- Text by John Bleho

Similar stories

Are we getting tafenoquine dosing right?

Researchers analysing clinical trial data for the new antimalarial drug tafenoquine find that higher doses are needed to cure reliably vivax malaria infection.

New SMRU building opened in Thailand to provide health care to marginalized populations

The inauguration of a new joint Shoklo Malaria Research Unit (SMRU) and Borderland Health Foundation (BHF) Building took place in Mae Ramat, Thailand, this week.

Constant genetic surveillance necessary to keep multidrug-resistant malaria parasite strains in check, study finds

Continually monitoring malaria parasite populations is necessary to prevent outbreaks of previously dormant multidrug-resistant malaria strains, say University of Oxford researchers. Multidrug-resistant malaria parasite strains can rapidly grow or collapse in response to public health policy changes, say the researchers in a study published today in The Lancet.

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

Combating drug-resistant malaria

MORU research has contributed to strategies to eliminate malaria in the Greater Mekong Sub-region, helping to prevent the spread of drug-resistant malaria and improving health provision and outcomes for remote communities.